Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
18 hedge funds and large institutions have $7.33M invested in Aridis Pharmaceuticals Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
38% more funds holding
Funds holding: 13 → 18 (+5)
7% less capital invested
Capital invested by funds: $7.87M → $7.33M (-$542K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.94M |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$345K |
| 3 |
Millennium Management
New York
|
+$345K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$166K |
| 5 |
State Street
Boston,
Massachusetts
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.43M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$780K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$24K |
| 4 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$3K |
ARDS Hedge Fund Activity: Q3 2021 in Review
18 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q3 2021, worth a combined $7.33M — down 6.9% from $7.87M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ARDS positions and 3 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.94M. The largest seller was AIGH Capital Management, cutting an estimated $1.43M.
- 18 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q3 2021, up from 13 in Q2 2021.
- Funds reported $7.33M of Aridis Pharmaceuticals Inc. Common Stock stock for Q3 2021, down 6.9% quarter-over-quarter.
- 8 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +5 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q3 2021 was Armistice Capital, an estimated $4.94M added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q3 2021 was AIGH Capital Management, an estimated $1.43M sold.
Based on aggregated 13F filings for Q3 2021.